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Abstract
Background: Cardiovascular disease (CVD) is the major cause of death after renal transplantation. Not only
conventional CVD risk factors, but also transplant-specific risk factors can influence the development of CVD in
kidney transplant recipients.
The main objective of this study will be to determine the incidence of post-transplant CVD after renal
transplantation and related factors. A secondary objective will be to examine the ability of standard cardiovascular
risk scores (Framingham, Regicor, SCORE, and DORICA) to predict post-transplantation cardiovascular events in renal
transplant recipients, and to develop a new score for predicting the risk of CVD after kidney transplantation.
Methods/Design: Observational prospective cohort study of all kidney transplant recipients in the A Coruña
Hospital (Spain) in the period 1981-2008 (2059 transplants corresponding to 1794 patients).
The variables included will be: donor and recipient characteristics, chronic kidney disease-related risk factors, pre-
transplant and post-transplant cardiovascular risk factors, routine biochemistry, and immunosuppressive,
antihypertensive and lipid-lowering treatment. The events studied in the follow-up will be: patient and graft
survival, acute rejection episodes and cardiovascular events (myocardial infarction, invasive coronary artery therapy,
cerebral vascular events, new-onset angina, congestive heart failure, rhythm disturbances and peripheral vascular
disease).
Four cardiovascular risk scores were calculated at the time of transplantation: the Framingham score, the European
Systematic Coronary Risk Evaluation (SCORE) equation, and the REGICOR (Registre Gironí del COR (Gerona Heart
Registry)), and DORICA (Dyslipidemia, Obesity, and Cardiovascular Risk) functions.
The cumulative incidence of cardiovascular events will be analyzed by competing risk survival methods. The clinical
relevance of different variables will be calculated using the ARR (Absolute Risk Reduction), RRR (Relative Risk
Reduction) and NNT (Number Needed to Treat).
The ability of different cardiovascular risk scores to predict cardiovascular events will be analyzed by using the c
index and the area under ROC curves. Based on the competing risks analysis, a nomogram to predict the
probability of cardiovascular events after kidney transplantation will be developed.
Discussion: This study will make it possible to determine the post-transplant incidence of cardiovascular events in
a large cohort of renal transplant recipients in Spain, to confirm the relationship between traditional and
transplant-specific cardiovascular risk factors and CVD, and to develop a score to predict the risk of CVD in these
patients.
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Background
Cardiovascular disease (CVD) is one of the most common
complications after renal transplantation, with a consider-
ably higher incidence than in the general population [1].
Although in recent years some authors have documented
a significant reduction in cardiovascular death after kidney
transplantation [2], today CVD is still the major known
cause of death in kidney transplant patients [3].
In addition to the conventional CVD risk factors (such
as obesity, smoking habits, diabetes, hypertension or
dyslipidemia), several other factors seem to influence
the high incidence of cardiovascular events in renal
transplant patients [4,5]. These include, amongst others,
the duration of prior dialysis [6-8], graft function after
transplantation [9-11], hyperhomocysteinemia [12-16],
elevated inflammatory markers [16-18], proteinuria
[19-22], acute rejection episodes [23], post-transplant
diabetes mellitus [6,24-27], and the toxic effects derived
from the use of immunosuppressant medications and
other drugs [28,29].
Therefore, when evaluating patients prior to kidney
transplantation, special attention should be given to car-
diovascular risk factors. To determine the individual risk
of cardiovascular events, risk scores have been estab-
lished in general populations, such as the Framingham
Heart Study score [30,31], the Regicor (Framingham
calibrated to Spain) [32], SCORE [33] or DORICA [34].
However, the validity of these equations in more
selected populations, such as those of transplant
patients, is not well established. In renal transplant reci-
pients, the Framingham score does not seem to accu-
rately predict the individual cardiovascular risk, leading
to an underestimation of the cardiovascular event rates
[4,16]. A recent study has corroborated the poor predic-
tive accuracy of the Framingham score in these patients,
indicating the need to consider new predictive models
that incorporate both traditional and non-traditional
cardiovascular risk factors [35].
Determining the incidence of cardiovascular events
after a kidney transplant and the associated risk factors
is therefore important in order to inform physicians of
the need for CVD screening and prevention as part of
the transplant evaluation [36]. Moreover, an accurate
estimation of a patient’s risk of cardiovascular disease
could make it possible to identify people at high risk of
suffering a cardiovascular event, and intervene proac-
tively before they develop the disease.
This project was designed with three main objectives:
firstly, to determine the incidence of post-transplant car-
diovascular events after renal transplantation and related
factors; secondly, to examine the ability of established
cardiovascular risk scores (Framingham, Regicor,
SCORE, and DORICA) to predict post-transplantation
cardiovascular events in renal transplant recipients; and
finally, to develop and validate a cardiovascular risk
score to predict the risk of developing a cardiovascular
event after kidney transplantation.
Methods/Design
Design and study population
Observational, retrospective and prospective cohort
study of all adult (> 18 years) patients who underwent
primary or repeated kidney transplantation with a graft
from a cadaveric or living donor in the A Coruña Hos-
pital (northwest Spain) between 1 January 1981 and 31
December 2008. Patients who had undergone simulta-
neous kidney-pancreas transplantation will be excluded
from the analysis.
Measurements
All the variables that will be recorded for each one of
the patients included in the study are summarized in
Additional file 1: Table S1.
Characteristics recorded at the time of transplantation
include donor and recipient age and gender, body
weight, height, body mass index (weight in kilograms
divided by the height in meters squared), primary cause
of renal failure (type I diabetes mellitus, type II diabetes
mellitus, primary glomerulonephritis, nephrosclerosis
including hypertension and renovascular disease, poly-
cystic kidney disease, systemic lupus erythematosus, and
others), cold ischemia time, type of dialysis prior to
transplant (hemodialysis or peritoneal dialysis), total
duration of renal replacement therapy before transplan-
tation, and previous transplants. The date of transplan-
tation and the type of donor (a deceased or living
donor) will also be recorded.
Information about other traditional cardiovascular risk
factors at the time of transplantation will also be col-
lected, including history of tobacco smoking, hyperten-
sion, hypercholesterolemia, left ventricular hypertrophy,
prior diabetes and a history of cerebrovascular disease
(transient ischemic attacks and strokes), peripheral vas-
cular disease (revascularization procedures and amputa-
tions) and malignancies prior to transplantation.
After transplantation, episodes of acute rejection and
infections will be registered, together with the patient’s
smoking status, new-onset diabetes and diagnosis of left
ventricle hypertrophy. Biochemical parameters will be
collected during the post-transplantation follow-up at
week 1, week 2, month 1, month 3, month 6, and yearly
thereafter. These will include white blood counts, hema-
tocrit, haemoglobin, cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, triglycerides, creatinine levels and 24-hour protei-
nuria. At the same time intervals, systolic and diastolic
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blood pressure will be recorded. Renal function will be
estimated using the Cockcroft-Gault formula [37] and
the modified Modification of Diet in Renal Disease
(MDRD) equation [38]. In the analysis of factors pre-
dicting new post-transplant cardiovascular events, the
average of laboratory and blood pressure values
recorded before the event will be considered.
For the analysis, the cut-points defining the control of
each risk factor will be taken from the European Guide-
lines on CVD prevention [39]. For estimates of dyslipi-
demia control based on LDL, HDL cholesterol and
triglycerides, we will use the cut-points agreed in the
consensus statement from the American Diabetes Asso-
ciation and the American College of Cardiology Founda-
tion [40].
The initial immunosuppressive regimen of the patients
and changes in treatment during follow-up will be
recorded. Dosage of immunosuppressive drugs will also
be registered after transplantation at week 1, week 2,
months 1, 3 and 6, and yearly thereafter. The use of
antihypertensive and lipid-lowering drugs after trans-
plantation will also be registered at the same times.
Post-transplant cardiovascular events are defined as
the presence of myocardial infarction, invasive coronary
artery therapy, cerebral vascular events (stroke and tran-
sient ischemic attacks), new-onset angina, congestive
heart failure, rhythm disturbances (ventricular tachycar-
dia, atrial fibrillation and the need for a pacemaker), and
peripheral vascular disease. Peripheral vascular disease is
defined as the need for invasive therapy or conserva-
tively managed limb gangrene.
Patients will be followed-up from the date of renal
transplantation until death or their return to dialysis.
Quantification of cardiovascular risk
Four established cardiovascular risk scores will be
applied to the kidney transplant recipients at the time of
transplantation: the Framingham risk factor score, the
European Systematic Coronary Risk Evaluation (SCORE)
equation, and two coronary risk equations that use the
calibrated Framingham functions for the Spanish popu-
lation, the REGICOR (Registre Gironí del COR (Gerona
Heart Registry)) and DORICA (Dyslipidemia, Obesity,
and Cardiovascular Risk) functions.
The Framingham risk score will be calculated using
both the classic Framingham-Anderson equation [30]
and the equation modified by Wilson [31]. These scores
predict the risk of developing fatal or non-fatal coronary
heart disease (CHD) within a 10-year time period in
adults between the ages of 30-74 with no known
previous history of CHD, stroke, or peripheral vascular
disease. CHD includes angina pectoris, myocardial
infarction, coronary insufficiency (unstable angina) and
coronary heart death.
The original Framingham-Anderson equation includes
the following risk factors: age, sex, systolic blood pres-
sure, total cholesterol, HDL-cholesterol, diabetic status,
tobacco smoking status and evidence of left ventricular
hypertrophy on resting electrocardiogram (ECG). The
Framingham-Wilson equation replaces the continuous
measurements of systolic blood pressure, total choles-
terol and HDL-cholesterol with categorical variables
based on the risk categories of the Joint National Com-
mittee on Blood Pressure and the National Cholesterol
Education Program (NCEP) [41-43]. It also takes into
account information regarding diastolic and LDL-choles-
terol levels, and does not include the diagnosis of left
ventricular hypertrophy due to its high association with
hypertension and the absence of standard, universally
accepted ECG criteria.
The European SCORE was developed by the European
Society of Cardiology in 2003 as an estimation of
10-year risk of fatal cardiovascular disease (CVD) in
subjects between the ages of 24 and 80. The variables
used to calculate this score include age, gender, total
cholesterol, systolic blood pressure and current smoking
status [33]. The main difference between the SCORE
risk chart and the Framingham model is that it esti-
mates the risk for all atherothrombotic cardiovascular
manifestations, including stroke, heart failure, peripheral
arterial insufficiency or certain aneurysms, and not just
CHD. The SCORE charts are currently the CVD charts
recommended by the European Societies [44] and the
Spanish Interdisciplinary Committee for Cardiovascular
Disease Prevention (CEIPC) [45]. The SCORE risk
charts calibrated for Spain will be used [46].
Finally, the REGICOR [32] and the DORICA [34]
charts are adaptations of the Framingham equation
to the Spanish population characteristics. Like the
Framingham equation, these functions estimate the risk
of coronary mortality and morbidity using information
about age, gender, total cholesterol, HDL-cholesterol,
systolic and diastolic blood pressure and smoking habits,
differentiating diabetic from non-diabetic patients.
Patients will be classified as high-risk patients when their
ten-year risk of coronary heart disease is ≥20% according
to Framingham [31], REGICOR [32] and DORICA [34]
equations or when their ten-year risk of cardiovascular
mortality is ≥5% according to the SCORE system [44].
Sample size
During the study period (1981-2008) n = 2059 kidney
transplants were performed in the A Coruña Hospital,
corresponding to 1794 patients.
This sample size will make it possible to detect as sig-
nificant, in a Cox regression model, a relative risk of
1.33 or more associated with a prevalence of exposure
to a cardiovascular risk factor of 50% and a censored
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data percentage of 78% (Security: 95%; Statistical power:
80%). Assuming an exposure prevalence of 50% maxi-
mizes the sample size necessary to detect a relative risk
of this magnitude. According to previously published
data for this cohort of patients, the estimated incidence
of CVD at five years is 22.2% [47], and so the censoring
value was estimated at 78%. In this situation, the sample
size required to estimate a relative risk of 1.33 or more
(a = 0.05, b = 0.2) would be n = 1755 patients.
Statistical analysis
A descriptive analysis of the variables recorded will be
performed. Observed frequencies and percentages will
be used for qualitative variables, with their 95% confi-
dence interval, and the mean and standard deviation or
median and interquartilic range for quantitative
variables.
The primary outcome for this study will be the esti-
mation of the probability of cardiovascular disease in
the presence of other competitive events in renal trans-
plant patients. The cumulative incidence of cardiovascu-
lar events after kidney transplantation will be analyzed
by competing risk survival methods, where each subject
is at risk of failure from different causes. Therefore,
each patient will be classified in four states of interest
(alive with functioning graft, death, graft failure and car-
diovascular disease).
Cumulative incidence functions will be used to com-
pare the observed incidence of events between groups
[48]. The cumulative incidence function regression
model of Fine and Gray will be used for multiple regres-
sion analyses [49]. Additionally, the clinical relevance of
different variables will be evaluated using the ARR
(Absolute Risk Reduction), RRR (Relative Risk Reduc-
tion) and NNT (Number Needed to Treat).
In order to analyze the ability of each of the four car-
diovascular risk scores to predict cardiovascular events
rates, the concordance c index [50] and the area under
the receiver-operating characteristic (ROC) curves, using
a time-dependent approach [51], will be calculated. To
calibrate the scores, relative risk ratios for observed-to-
predicted event rates will be computed, and the Hos-
mer-Lemeshow test will be applied.
Based on the competing risks analysis, a nomogram to
estimate the probability of cardiovascular events after
kidney transplantation will be developed. The objective
is to use the conditional cumulative incidence function
to provide a patient-specific prediction of the probability
of failure in the setting of competing risks.
The predictive performance of the nomogram will be
evaluated by assessing both discrimination and calibra-
tion values [52]. A bootstrap re-sampling approach with
1000 replications will be used to reduce overfit bias.
Discrimination will be quantified with the concordance
c index and the area under the receiving operating char-
acteristic (ROC) curve [50,51]. The nomogram will then
be calibrated graphically, comparing the predicted prob-
abilities with the actual rate of patients with cardiovas-
cular events. A Loess curve will be fitted to the data and
compared with an ideal fit. In addition, the Brier score
will be calculated as a measure of the predictive accu-
racy of the model.
A p-value of < 0.05 will be considered as statistically
significant (two-sided). Statistical analyses will be carried
out with SPSS version 17.0 (SPSS Inc., Chicago, IL.) and
R version 2.9.1 (The R Foundation for Statistical Com-
puting), adding the ROCR, Design and Hmisc libraries.
Ethics
The study has received written approval from the
regional Ethics Committee for Clinical Research (CEIC
Galicia) (code 2007/019). Informed consent will be
obtained from all the participants in the study.
Discussion
In recent years, several important changes have occurred
in the management of kidney transplant patients that
have been associated with an improvement in rejection
rates and early graft survival [53]. Therefore, attention is
now focusing on improving long-term transplant out-
comes [3]. Renal dysfunction and increased cardiovascu-
lar risk are some of the factors that have a negative
impact on long-term graft and patient survival.
Although some authors have documented a reduction in
CVD-related deaths in kidney transplant recipients in
recent years, CVD is still the leading cause of death in
patients with a functioning allograft [2].
Several studies have analyzed the risk factors con-
nected with the incidence of cardiovascular events after
kidney transplantation [4-29]. However, the role of
some novel risk factors remains unclear. Furthermore,
most of the previous studies are based on retrospective
analyses of registry data, which contains information
only on baseline data at the time of transplantation and
the immediate post-transplantation follow-up. As a
result, long-term follow-up data on clinical, biochemical
and treatment covariates after transplantation is not
always available.
This study will allow us to determine the post-
transplant incidence of cardiovascular events in a cohort
of renal transplant recipients in Spain, as well as to con-
firm the relationship between some CVD risk factors
and the occurrence of a cardiovascular event in these
patients. The development of a specific CVD risk score
for kidney transplant recipients would make it possible
to identify patients at high risk for coronary events at
the time of transplantation, or shortly after the trans-
plant. Therefore, this risk assessment could be used to
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recommend lifestyle changes for patients, to initiate
appropriate treatment, or to redesign the immunosup-
pressive regimens for the prevention of primary or
recurrent cardiovascular events in kidney transplant
patients. The majority of studies use survival analysis
strategies with the methodology of Kaplan and Meier.
As this methodology may lead to overestimating the
likelihood of the occurrence of the events of interest, we
propose a competitive risk analysis in order to study the
prognosis of these patients [48,49].
One of the limitations of this study is that information
will mostly be taken retrospectively from hospital
records, which could lead to information bias. On the
other hand, transplant recipients are subjected to a
more exhaustive follow-up than normal, not only during
the immediate post-transplant period, but also during
the years after the transplant. This fact would minimize
any possible information bias. Likewise, during the study
period standard immunosuppressive therapy has chan-
ged, and the treatment for each patient will depend on
the date of transplantation and other medical subjective
criteria. In order to control the changes that have
occurred over the years, adjustments will be made based
on the year of transplantation. Also, the therapeutic
changes that occurred during the follow-up period for
each of the patients will make it difficult to establish
relationships between the medication and the cardiovas-
cular events. Therefore, the impact of immunosuppres-
sant medication on the presence of cardiovascular
events in the follow-up could not be well established.
The role of immunosuppressant agents must be investi-
gated in greater detail with randomized clinical studies,
and not with observational studies of this kind. How-
ever, our study will include a large cohort of patients
with a long follow-up period, and the sample size is
expected to be large enough both to identify individual
CVD risk factors from multivariate analysis and to
develop a new CVD prediction model.
Additional material
Additional file 1: Table S1, Study measurements. Table displaying the
measurements that will be recorded on each patient at the time of
transplantation and during the follow-up.
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